NovoCure/NVCR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About NovoCure

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Ticker

NVCR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Asaf Danziger

Employees

1,453

Headquarters

Saint helier, Jersey

NovoCure Metrics

BasicAdvanced
$2.4B
Market cap
-
P/E ratio
-$1.81
EPS
0.78
Beta
-
Dividend rate
$2.4B
0.78245
$82.64
$10.87
1.4M
6.258
5.993
158.521
158.521
-16.79%
-48.70%
-19.40%
4.506
6.591
6.591
0.61%
-34.70%
1.00%

What the Analysts think about NovoCure

Analyst Ratings

Majority rating from 7 analysts.
Hold

NovoCure Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-27.94% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$139M
3.59%
Net income
-$39M
-17.66%
Profit margin
-27.94%
-20.51%

NovoCure Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 14.84%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.54
-$0.46
-$0.45
-$0.36
-
Expected
-$0.50
-$0.53
-$0.52
-$0.42
-$0.42
Surprise
7.91%
-12.38%
-13.70%
-14.84%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for NovoCure stock?

NovoCure (NVCR) has a market cap of $2.4B as of June 15, 2024.

What is the P/E ratio for NovoCure stock?

The price to earnings (P/E) ratio for NovoCure (NVCR) stock is 0 as of June 15, 2024.

Does NovoCure stock pay dividends?

No, NovoCure (NVCR) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next NovoCure dividend payment date?

NovoCure (NVCR) stock does not pay dividends to its shareholders.

What is the beta indicator for NovoCure?

NovoCure (NVCR) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the NovoCure stock price target?

The target price for NovoCure (NVCR) stock is $27.42, which is NaN% below the current price of $. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell NovoCure stock

Buy or sell NovoCure stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing